State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China
Auto-generated profile, based on publicly available information
Long Bai
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China
Background: The prognostic value of lactate dehydrogenase (LDH) in colorectal cancer patients has remained inconsistent between nonmetastatic and metastatic settings. So far, very few studies have included LDH in the prognostic analysis of curative‐intent surgery for colorectal liver metastases (CRLM).Patients and Methods: Five hundred and eighty consecutive metastatic colorectal cancer patients who underwent curative‐intent CRLM resection from Sun Yat‐sen University Cancer Center (434 patients) and Sun Yat‐sen University Sixth Affiliated Hospital (146 patients) in 2000–2019 were retrospectively collected. Overall survival (OS) was the primary end point. Cox regression model was performed to identify the prognostic values of preoperative serum LDH levels and other clinicopathology variables. A modification of the established Fong CRS scoring system comprising LDH was developed within this Chinese population.Results: At the median follow‐up time of 60.5 months, median OS was 59.5 months in the pooled cohort. In the multivariate analysis, preoperative LDH >upper limit of normal (250 U/L) was the strongest independent prognostic factor for OS (HR 1.73, 95% confidence interval [CI], 1.22–2.44; p < 0.001). Patients with elevated LDH levels showed impaired OS than patients with normal LDH levels (27.6 months vs. 68.8 months). Five‐year survival rates were 53.7% and 22.5% in the LDH‐normal group and LDH‐high group, respectively. Similar results were also confirmed in each cohort. In the subgroup analysis, LDH could distinguish the survival regardless of most established prognostic factors (number and size of CRLM, surgical margin, extrahepatic metastases, CEA, and CA19‐9 levels, etc.). Integrating LDH into the Fong score contributed to an improvement in the predictive value.Conclusion: Our study implicates serum LDH as a reliable and independent laboratory biomarker to predict the clinical outcome of curative‐intent surgery for CRLM. Composite of LDH and Fong score is a potential stratification tool for CRLM resection. Prospective, international studies are needed to validate these results across diverse populations.
Background: Colorectal cancer liver metastasis (CRLM) is a determining factor affecting the survival of colorectal cancer (CRC) patients. This study aims at developing a novel prognostic stratification tool for CRLM resection. Methods: In this retrospective study, 666 CRC patients who underwent complete CRLM resection from two Chinese medical institutions between 2001 and 2016 were classified into the training (341 patients) and validation (325 patients) cohorts. The primary endpoint was overall survival (OS). Associations between clinicopathological variables, circulating lipid and inflammation biomarkers, and OS were explored. The five most significant prognostic factors were incorporated into the Circulating Lipid- and Inflammation-based Risk (CLIR) score. The predictive ability of the CLIR score and Fong’s Clinical Risk Score (CRS) was compared by time-dependent receiver operating characteristic (ROC) analysis. Results: Five independent predictors associated with worse OS were identified in the training cohort: number of CRLMs >4, maximum diameter of CRLM >4.4 cm, primary lymph node-positive, serum lactate dehydrogenase (LDH) level >250.5 U/L, and serum low-density lipoprotein-cholesterol (LDL-C)/high-density lipoprotein-cholesterol (HDL-C) ratio >2.9. These predictors were included in the CLIR score and each factor was assigned one point. Median OS for the low (score 0–1)-, intermediate (score 2–3)-, and high (score 4–5)-risk groups was 134.0 months, 39.9 months, and 18.7 months in the pooled cohort. The CLIR score outperformed the Fong score with superior discriminatory capacities for OS and RFS, both in the training and validation cohorts. Conclusions: The CLIR score demonstrated a promising ability to predict the long-term survival of CRC patients after complete hepatic resection.
6 February 2026 in Cancer Treatment and Research Communications
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of cholesterol metabolism homeostasis. However, its significance in colorectal cancer liver metastasis (CRLM) remains undetermined. Here, we evaluated PCSK9 expression and its prognostic value in patients undergoing curative-intent resection for CRLM. We retrospectively analyzed data from 148 patients with CRLM who underwent curative-intent liver resection at Sun Yat-sen University Cancer Center between March 2009 and December 2016. We measured PCSK9 expressions in paraffin-embedded surgical specimens of CRLM using immunohistochemistry (IHC) and in plasma using enzyme-linked immunosorbent assay (ELISA). Additionally, we examined their immune profiles and correlated them with PCSK9 expression. PCSK9 expression was detected in 68.9 % (102/148) of the analyzed CRLM specimens. Patients with high PCSK9 expression (defined as IHC score > median) had significantly worse median OS (not reached vs. 46.2 months; hazard ratio [HR] 1.79, 95 % confidence interval [CI] 1.11-2.89; P = 0.016) and RFS (31.0 vs. 12.0 months; HR 1.85, 95 % CI 1.19-2.87; P = 0.006) compared to those with low expression. Moreover, patients with a plasma PCSK9 concentration above 75.4 ng/ml also exhibited worse OS (47.8 vs. 141.9 months, P = 0.016) and RFS (17.0 vs. 47.0 months, P = 0.047). High PCSK9 expression was associated with an increased immune proportion score (IPS) for programmed cell death-ligand 1 (PD-L1) within the metastatic site. Our study indicates that both tissue and plasma PCSK9 expressions hold promise as prognostic biomarkers for curative-intent resection of CRLM.